Search This Blog

1

Labels

Cancer (150) Breast (38) Study (38) Health (32) Patients (31) Treatment (27) Could (23) Therapy (19) Research (17) Against (12) Blood (11) Disease (11) linked (11) Diabetes (10) Early (10) Prevent (10) Survival (10) Treatments (7) higher (7) surgery (7) Might (6) Prostate (6) Tumors (6) During (5) Effects (5) Growth (5) Chemotherapy (4) Drinking (4) Prevention (4) Obama (3) Obesity (3) Without (3) associated (3) Experts (2) Important (2) Infection (2) About (1) Analysis (1) Causes (1) Eliminate (1) stroke (1)

AD

Saturday, April 26, 2014

Florida overcomes GOP barriers to enroll uninsured

MIAMI (AP) — Florida's Republican leaders have fought the Affordable Care Act at every turn, banning navigators from county health departments, offering no state dollars to boost outreach efforts to 3.5 million uninsured and leading the fight to repeal the law. Yet the state has emerged as a tale of what went right with President Barack Obama's health care overhaul.

More than 440,000 Florida residents had been enrolled through the federal marketplace through the end of February.

Florida's success is due partly to infrastructure created in the swing state by Democratic-affiliated groups during the last three presidential elections, along with continued investment by the Obama administration and nonprofit advocacy groups in the diverse state that will be competitive in November's midterm election.

___

Kennedy can be followed on Twitter https://twitter.com/kkennedyAP


View the original article here

Friday, April 25, 2014

Treasury says Lew leaves hospital after surgery

WASHINGTON (Reuters) - U.S. Treasury Secretary Jack Lew was discharged from a hospital on Wednesday following a surgery to treat a benign enlarged prostate, a Treasury spokesperson said.

"(Lew) is now at home recuperating from his surgical procedure yesterday," Treasury spokeswoman Natalie Wyeth Earnest said in a statement. "He is in good spirits, talking with staff, and looks forward to being back in the office next week."

The spokeswoman had said on Tuesday the surgery went well but that Lew's doctor decided to keep him in the hospital overnight because he was running a low fever.

Lew, 58, was sworn in as Treasury secretary in February 2013 after serving as President Barack Obama's chief of staff.

(Reporting by Timothy Ahmann; Editing by Chizu Nomiyama)


View the original article here

Thursday, April 24, 2014

Doctors Really Do Raise Your Blood Pressure

WEDNESDAY, March 26, 2014 (HealthDay News) -- Patients' blood pressure readings are notably higher when they're taken by a doctor than by a nurse, a new study finds.

This link between doctors and higher blood pressure readings is known as the "white coat effect," and is believed to be the result of patients being more nervous when examined by a physician.

This effect has been noted in a number of previous studies, but this new paper is the first to confirm it, according to the study authors.

The investigators analyzed data from more than 1,000 people who had blood pressure readings taken by both doctors and nurses during the same visit. The readings taken by doctors were significantly higher than those taken by nurses, the study authors found.

The findings, published in the current issue of the British Journal of General Practice, should lead to changes in the way blood pressure readings are taken, according to lead author Dr. Christopher Clark, of the University of Exeter Medical School, in England.

"Doctors should continue to measure blood pressure as part of the assessment of an ill patient or a routine check-up, but not where clinical decisions on blood pressure treatment depend on the outcome," Clark said in a university news release.

"The difference we noted is enough to tip some patients over the threshold for treatment for high blood pressure, and unnecessary medication can lead to unwanted side-effects," he said.

"Some patients may be erroneously asked to continue to monitor their own blood pressure at home, which can build anxiety. These inappropriate measures could all be avoided by the simple measure of someone other than a doctor taking the blood pressure recording," Clark added.

He suggested that researchers "should also think carefully about how to account for this effect in studies that compare treatment by doctors and nurses. Some studies have concluded that nurses are better at treating [high blood pressure], when in fact those findings could be down to this recording bias."

More information

The U.S. National Heart, Lung, and Blood Institute explains how to prevent high blood pressure.

Copyright c 2014?HealthDay. All rights reserved.


View the original article here

Tuesday, April 22, 2014

Virginia lawmakers recess without Medicaid, budget deal

By Gary Robertson

RICHMOND, Virginia (Reuters) - Virginia's legislature has recessed without reaching agreement with Democratic Governor Terry McAuliffe over a budget or Medicaid expansion.

McAuliffe, a former Democratic Party fundraiser, and the Republican-dominated House of Delegates are deadlocked over a two-year pilot expansion of Medicaid, the federal healthcare program for the poor the governor has proposed.

House lawmakers meeting in a two-day special session defeated McAuliffe's proposed $96 billion two-year budget late on Tuesday. The House then passed its own version of the budget without Medicaid expansion, seen as a priority for the governor, before adjourning.

The Democratic-controlled state Senate will reconvene April 7 to take up the budget fight anew. A budget must be approved by June 30 or risk state operations starting to shut down.

Republicans are asking McAuliffe to deal with the budget and Medicaid in separate sessions.

"We would be more than happy to debate Medicaid in a special session," said Kirk Cox, Republican House majority leader. "I think is afraid he loses all his leverage without the budget."

McAuliffe, who made Medicaid expansion the centerpiece of his gubernatorial campaign last year, has not responded to the rebuff.

But he has said that accepting $2 billion in federal funds to expand Medicaid under the Affordable Care Act would release money that could be used to create jobs, raise state salaries, bolster pensions and implement health reforms.

(Editing by Ian Simpson and Gunna Dickson)


View the original article here

Monday, April 21, 2014

One in 25 patients battling hospital-acquired infections: CDC

By Gene Emery

NEW YORK (Reuters Health) - On any given day, one in 25 hospitalized patients - 4 percent - is battling an infection picked up in a hospital or other healthcare facility, according to a new survey by the Centers for Disease Control and Prevention (CDC).

That translates to more than 600,000 hospital patients each year. Roughly 74,000 of them have to fight more than one hospital-acquired infection, researchers found.

About half of those infections were either linked to a device attached to the patient, like a catheter or ventilator, or occurred after a surgical procedure at the site of the surgery.

Previous estimates had pegged the annual number of infections at 2.1 million in the 1970s and 1.7 million from 1990 through 2002.

"The trend, in magnitude, seems to be going in the right direction," Dr. Mike Bell, deputy director of the Division of Healthcare Quality Promotion at the CDC, told Reuters Health.

Despite continuing concern about hospital-acquired infections, especially ones that are resistant to antibiotics, the U.S. does not have a national system for collecting information on the problem.

The new study, led by Dr. Shelley S. Magill of the CDC and published in the New England Journal of Medicine, was based on an analysis of 11,282 patients treated at 183 hospitals in 10 states. The survey in each hospital was done over the course of a day, involving as many as 100 patients per facility.

Pneumonia accounted for about 22 percent of the hospital-acquired infections. Another 22 percent were infections at the surgical site, and 17 percent were stomach or intestinal illnesses. Urinary tract and bloodstream infections ranked fourth and fifth, respectively.

The most common bacterium responsible was Clostridium difficile, which kills an estimated 14,000 people in the U.S. each year. It was detected in 12 percent of the hospital-acquired illnesses and was responsible for 71 percent of gastrointestinal infections in particular.

Nursing homes, emergency departments, rehabilitation hospitals and outpatient treatment centers were not included in the tally.

The researchers estimated that in 2011, 648,000 hospitalized patients had to battle at least one hospital-acquired infection. The total number of infections was estimated at 721,800. To put that number in perspective, about 34 million people are admitted to 5,000 community hospitals in the U.S. each year.

The new report "validates the work we've been doing, focusing on some of the severe infections related to intensive care, related to devices such as catheters in the bloodstream or the bladder, mechanical ventilation or surgical procedures," Bell said.

To prevent infections, the National Patient Safety Foundation recommends patients wash their hands regularly and remind their doctors and nurses to do the same. Patients should also make sure both bandages and the skin around any catheters are kept clean and dry, it says.

SOURCE: http://bit.ly/1rzGOHe New England Journal of Medicine, online March 26, 2014.


View the original article here

Saturday, April 19, 2014

Exclusive: Baxter explores sale of its vaccines business - sources

By Olivia Oran and Arno Schuetze and Soyoung Kim

NEW YORK/FRANKFURT (Reuters) - Baxter International Inc is exploring a sale of its vaccines business, according to people familiar with the matter, the latest healthcare company to look at divesting non-core assets to focus on key strengths.

The medical equipment and pharmaceuticals company is working with Goldman Sachs Group to find a buyer for the unit and has reached out to potentially interested parties including private equity firms, the people said on Wednesday, asking not to be named because the matter is not public.

The Baxter unit, which includes vaccines for meningitis C and tick-borne encephalitis as well as collaborations for the development of seasonal and pandemic influenza vaccines, had 2013 sales of close to $300 million according to regulatory filings.

It could not be learned how much the business could fetch in a sale, as the deliberation is at an early stage and Baxter has yet to send out detailed financial information to potential buyers, the people added.

Representatives for Baxter did not immediately respond to requests for comment. Goldman Sachs declined to comment.

The vaccines business, which is part of Baxter's $6.5 billion BioScience segment, is profitable but the company has determined it is not core, one person said.

Deerfield, Illinois-based Baxter makes medical devices, pharmaceuticals and biotechnology products, focusing on areas including hemophilia, immune disorders and infectious diseases.

It divides its operations between the BioScience division, which makes products including plasma-based proteins to treat hemophilia, and a Medical Products division. The medical products unit makes equipment used to inject fluids and drugs and had 2013 sales of nearly $8.7 billion.

Baxter is yet another example of large healthcare companies seeking to sell or spin off smaller divisions so they can focus on their mainstay products and allocate capital better. They have shown a new willingness to consider whether other companies may be better owners for certain assets.

Novartis AG is taking a hard look at its sub-scale businesses -- animal health, vaccines and over-the-counter medicines -- for a potential divestiture, chief executive Joe Jimenez told Reuters last week, adding that at least one of the three is not expected to make the cut.

Merck & Co Inc is also in talks with several companies about selling its consumer healthcare business, a deal that could value the unit at between $10 billion and $12 billion, Reuters previously reported.

(Reporting by Olivia Oran, Soyoung Kim in New York and Arno Schuetz in Frankfurt; editing by Andrew Hay)


View the original article here

Friday, April 18, 2014

Breast Cancer Startup Challenge Inventions and Winners

The Avon Foundation for Women, in partnership with NCI and the Center for Advancing Innovation (CAI), have announced the ten winners of a world-wide competition to accelerate the process of bringing emerging breast cancer research technologies to market.

Each team was required to produce a short video explaining and highlighting their ideas.? The videos are from the winners of the Breast Cancer Startup Challenge.? This listing does not constitute NCI’s endorsement of the companies or potential products and does not guarantee a grant of license for any federally-owned technology.

Videos from the winning teams are below.

Challenge #1. Diagnostic from Biopsies with Software Analysis
Category: Diagnostics/Health IT
Lead Inventor: Tom Misteli, PhD, NCI
Winner: University of Cambridge

YouTube Preview Image

‧

‧

Challenge #2 -Immunotherapy Using Modified Self Tumor Cells
Category: Therapeutic
Lead Inventor: Dennis Klinman, M.D., Ph.D., NCI
Winner: Washington University in Saint Louis

YouTube Preview Image

‧

‧

Challenge #3 – Combination of Tissue Reconstruction and Recurrence Prevention
Category: Device/Therapeutic
Lead Inventor: Karen Burg, Ph.D., Clemson University
Winner: Tulane University
YouTube Preview Image

Finalist: Clemson University
YouTube Preview Image

‧

‧

Challenge #4 – Human monoclonal Antibody Based Cancer Therapies
Category: Therapeutic, Diagnostic
Lead Inventor: Mitchell Ho, Ph.D., NCI
Winner: Stanford University

YouTube Preview Image

‧

‧

Challenge #5 -Immunotherapy Using Granulysin Activated Monocytes
Category: Therapeutic
Lead Inventor: Alan Krensky, M.D., Northwestern University
Winner: Northwestern University

YouTube Preview Image

‧

‧

Challenge #6 – Anti-cancer Toxin
Category: Therapeutic
Lead Inventor: Nadya Tarasova, Ph.D., NCI
Winner: Rutgers, The State University of New Jersey

YouTube Preview Image

‧

‧

Challenge #7 – Versatile Delivery Method for Cancer Therapeutics
Category: Vaccine or Drug Delivery (Protein or RNA)
Lead Inventors: Stanislaw J Kaczmarczyk, Ph.D. & Deb Chatterjee, Ph.D., NCI
Winner: University of Cambridge

YouTube Preview Image

Finalist: Wake Forest University
YouTube Preview Image

‧

‧

Challenge #8 -Genomic Based Diagnostic Assay
Category: Diagnostics and prognostic
Lead Inventor: Steven Libutti, M.D., FACS, NCI
Winner: University of California, Berkeley

YouTube Preview Image

‧

‧

Challenge #9 -Tissue-based Diagnostic Assay
Category: Diagnostic
Lead Inventor: Stephen M. Hewitt, M.D., Ph.D., NCI
Winner: McGill University

YouTube Preview Image

‧

‧

Challenge #10 – Diagnostic Kit for Therapy Benefit Prediction
Category: Diagnostic
Lead Inventor: Sherry Yang, MD., Ph.D., NCI
Winner: Tulane University

YouTube Preview Image Print This Post?Print This Post

View the original article here

Thursday, April 17, 2014

Biologists use sound to identify breeding grounds of endangered whales

Remote acoustic monitoring among endangered whales is the subject of a major article by two doctoral students in The College of Arts and Sciences.

Leanna Matthews and Jessica McCordic, members of the Parks Lab in the Department of Biology, have co-authored "Remote Acoustic Monitoring of North Atlantic Right Whales Reveals Seasonal and Diel Variations in Acoustic Behavior." The article appears in the current issue of PLOS ONE, an inclusive, peer-reviewed, open-access resource from the Public Library of Science in San Francisco.

Susan Parks, assistant professor of biology for whom the lab is named, says the article confirms what many conservationists fear -- that Roseway Basin, a heavily traveled shipping lane, off the coast of Nova Scotia, is a vital habitat area for the endangered North Atlantic right whale.

"Remote acoustic monitoring is an important tool for understanding patterns in animal communication, and studies on the seasonality of context-specific acoustic signals allow inferences to be made about the behavior and habitat use of certain species," says Parks, an expert in behavioral ecology, acoustic communication and marine science. "Our results support the hypothesis that the North Atlantic right whale's breeding season occurs mostly from August to November and that this basin is a widely used habitat area."

More than 30 percent of all right whales use Roseway Basin, part of a larger geological formation called the Scotian Shelf, throughout the year. With only 400-500 in existence, these whales, says Parks, must congregate in the basin to feed and find mates.

Already, the U.S. and Canadian governments have taken steps to redirect shipping traffic, in response to several fatal collisions with right whales.

Matthews, whose research includes animal behavior and physiology, says the object of the article is to determine how and when Roseway Basin is used for male breeding activities.

"Part of the answer lies in a loud 'gunshot' sound, made by the male whale," says Matthews, the article's lead author. "We're not exactly sure what the gunshot is, but we think it may be a male-to-male antagonistic signal or an advertisement to females. … During a two-year period, we used non-invasive acoustic monitoring to analyze gunshots at two locations on the Scotian Shelf. The resultant data has provided tremendous insights into the whales' feeding and mating habits."

Matthews and her team found that gunshot sound production occurred mainly in the autumn and, more often than not, at night. Researchers say this kind of information is essential to not only the individual fitness of each whale, but also the survival of the species, in general.

McCordic, whose research spans animal behavior and communication, says the observed seasonal increase in gunshot sound production is consistent with the current understanding of the right whale breeding season.

"Our results demonstrate that detection of gunshots with remote acoustic monitoring can be a reliable way to track shifts in distribution and changes in acoustic behavior, including possible mating activities," she says, acknowledging David Mellinger, associate professor of marine bioacoustics at Oregon State University, who collected and provided access to the recordings used in the study. "It also provides a better understanding of right whale behavior and what needs to be done with future conservation efforts."

Parks, who assisted with the article, is proud of her students' accomplishments.

"Right whales are increasingly rare, and Leanna's and Jessica's research helps us understand how to better protect them," she says. "By identifying potential breeding areas, we might be able to save this critically endangered species."

Story Source:

The above story is based on materials provided by Syracuse University. Note: Materials may be edited for content and length.


View the original article here

Wednesday, April 16, 2014

New video-based teaching tool helps students learn animal-based lab work

For students and scientists beginning animal-based lab work, seeing a research procedure performed by experts is by far the most effective method of learning. Now the Cambridge-based company, JoVE, releases the new online video-based tool, Model Organisms II, to revolutionize the teaching of fundamental experiments in the three most common laboratory organisms -- the mouse, chick and zebrafish.

"Each of these species makes unique demands upon researchers, both in terms of the steps required for their maintenance and reproduction, as well as the tools and techniques available to study them," said Aaron Kolski-Andreaco, PhD., JoVE's Chief Product Officer, "The Model Organisms II collection provides a great overview of these nuances, in addition to providing visual demonstrations of techniques essential to working with each model."

Contrary to the traditional, text-based educational materials, Model Organisms II presents a powerful combination of scientific animation with video demonstrations by scientists from leading research institutions around the world. This novel tool is the latest installment in JoVE Science Education database dedicated to teaching laboratory fundamentals through simple, easy-to-understand visual presentations. For universities and colleges, the JoVE Science Education videos are a valuable new resource for efficient teaching and research.

"I wanted to find justification for buying it, so I sent around a message to faculty in biology," said Michael Newman, a Head Librarian and Bibliographer at Stanford University, "Those things usually don't get much response, but this time I got some pretty enthusiastic replies."

Stanford subscribed to the JoVE Science Education database in December 2013, shortly after JoVE released this database. Over 100 institutions -- including those ranging from the Ivy League to community colleges -- also purchased a subscription within only three months following the product launch.

"I've used it as a class tool where students can watch a technique on the screen and then do it immediately afterwards, and for what they're going to do the next time the class meets, so they'll come in a little less blind," said assistant professor, Dr. Jason Kuehner of Emmanuel College in Boston, MA, "For something like western blotting this is really good. That's a fairly laborious technique with multiple steps, and for students it's very easy to get confused as to what each step in the protocol means."

You can view the Science Education content at www.jove.com/se.

Story Source:

The above story is based on materials provided by Journal of Visualized Experiments (JOVE). Note: Materials may be edited for content and length.


View the original article here

Tuesday, April 15, 2014

Sensing gravity with acid: Scientists discover role for protons in neurotransmission

While probing how organisms sense gravity and acceleration, scientists at the Marine Biological Laboratory (MBL) and the University of Utah uncovered evidence that acid (proton concentration) plays a key role in communication between neurons. The surprising discovery is reported this week in the Proceedings of the National Academy of Sciences.

The team, led by the late MBL senior scientist Stephen M. Highstein, discovered that sensory cells in the inner ear continuously transmit information on orientation of the head relative to gravity and low-frequency motion to the brain using protons as the key means of synaptic signal transmission. (The synapse is the structure that allows one neuron to communicate with another by passing a chemical or electrical signal between them.)

"This addresses how we sense gravity and other low-frequency inertial stimuli, like acceleration of an automobile or roll of an airplane," says co-author Richard Rabbitt, a professor at University of Utah and adjunct faculty member in the MBL's Program in Sensory Physiology and Behavior. "These are very long-lasting signals requiring a a synapse that does not fatigue or lose sensitivity over time. Use of protons to acidify the space between cells and transmit information from one cell to another could explain how the inner ear is able to sense tonic signals, such as gravity, in a robust and energy efficient way."

The team found that this novel mode of neurotransmission between the sensory cells (type 1 vestibular hair cells) and their target afferent neurons (calyx nerve terminals), which send signals to the brain, is continuous or nonquantal. This nonquantal transmission is unusual and, for low-frequency stimuli like gravity, is more energy efficient than traditional synapses in which chemical neurotransmitters are packaged in vesicles and released quantally.

The calyx nerve terminal has a ball-in-socket shape that envelopes the sensory hair cell and helps to capture protons exiting the cell. "The inner-ear vestibular system is the only place where this particular type of synapse is present," Rabbitt says. "But the fact that protons are playing a key role here suggests they are likely to act as important signaling molecules in other synapses as well."

Previously, Erik Jorgensen of University of Utah (who recently received a Lillie Research Innovation Award from the MBL and the University of Chicago) and colleagues discovered that protons act as signaling molecules between muscle cells in the worm C. elegans and play an important role in muscle contraction. The present paper is the first to demonstrate that protons also act directly as a nonquantal chemical neurotransmitter in concert with classical neurotransmission mechanisms. The discovery suggests that similar intercellular proton signaling mechanisms might be at play in the central nervous system.

Stephen Highstein, who died in January 2014, was associate director of the MBL's Program in Sensory Physiology and Behavior. Mary Anne Mann, a research associate in the program, also participated in this research, as did Gay Holstein of Mt. Sinai School of Medicine.

Story Source:

The above story is based on materials provided by Marine Biological Laboratory. The original article was written by Diana Kenney. Note: Materials may be edited for content and length.


View the original article here

Sunday, April 13, 2014

Blood-brain barrier repair after stroke may prevent chronic brain deficits

Following ischemic stroke, the integrity of the blood-brain barrier (BBB), which prevents harmful substances such as inflammatory molecules from entering the brain, can be impaired in cerebral areas distant from initial ischemic insult. This disruptive condition, known as diaschisis, can lead to chronic post-stroke deficits, University of South Florida researchers report.

In experiments using laboratory rats modeling ischemic stroke, USF investigators studied the consequences of the compromised BBB at the chronic post-stroke stage. Their findings appear in a recent issue of the Journal of Comparative Neurology.

"Following ischemic stroke, the pathological changes in remote areas of the brain likely contribute to chronic deficits," said neuroscientist and study lead author Svitlana Garbuzova-Davis, PhD, associate professor in the USF Health Department of Neurosurgery and Brain Repair. "These changes are often related to the loss of integrity of the BBB, a condition that should be considered in the development of strategies for treating stroke and its long-term effects."

Edward Haller of the USF Department of Integrative Biology, the coauthor who performed electron microscopy and contributed to image analysis, emphasized that "major BBB damage was found in endothelial and pericyte cells, leading to capillary leakage in both brain hemispheres." These findings were essential in demonstrating persistence of microvascular alterations in chronic ischemic stroke.

While acute stroke is life-threatening, the authors point out that survivors often suffer insufficient blood flow to many parts of the brain that can contribute to persistent damage and disability. Their previous investigation of subacute ischemic stroke showed far-reaching microvascular damage even in areas of the brain opposite from the initial stroke injury. While most studies of stroke and the BBB explore the acute phase of stroke and its effect on the blood-brain barrier, the present study revealed the longer-term effects in various parts of the brain.

The pathologic processes of stroke-induced vascular injury tend to occur in a "time-dependent manner," and can be separated into acute (minutes to hours), subacute (hours to days), and chronic (days to months). BBB incompetence during post-stroke changes is well-documented, with some studies showing the BBB opening can last up to four to five days after stroke. This suggests that harmful substances entering the brain during this prolonged BBB leakage might increase post-ischemic brain injury.

In this study, the researchers used laboratory rats modeling ischemic stroke and observed injury not only in the primary area of the stroke, but also in remote areas, where persistent BBB damage could cause chronic loss of competence.

"Our results showed that the compromised BBB integrity detected in post-ischemic rat cerebral hemisphere capillaries -- both ipsilateral and contralateral to initial stroke insult -- might indicate chronic diaschisis," Garbuzova-Davis said. "Widespread microvascular damage caused by endothelial cell impairment could aggravate neuronal deterioration. For this reason, chronic diaschisis poses as a therapeutic target for stroke."

The primary focus for therapy development could be restoring endothelial and/or astrocytic integrity towards BBB repair, which may be "beneficial for many chronic stroke patients," senior authors Cesar V. Borlongan and Paul R. Sanberg suggest. The researchers also recommend that cell therapy might be used to replace damaged endothelial cells.

"A combination of cell therapy and the inhibition of inflammatory factors crossing the blood-brain barrier may be a beneficial treatment for stroke," Garbuzova-Davis said.

Story Source:

The above story is based on materials provided by University of South Florida (USF Innovation). Note: Materials may be edited for content and length.


View the original article here

Saturday, April 12, 2014

Patient safety merits new review for modified medical devices, physician says

For patient safety, the U.S. Food and Drug Administration (FDA) should require that clinical data be submitted as part of a more rigorous re-evaluation of medical devices that are modified after approval, according to UC San Francisco physician scientists in a commentary published online March 24, 2014 in the Annals of Internal Medicine. According to authors Rita Redberg, MD, UCSF professor of medicine, and UCSF second-year medical student Sarah Zheng, such a requirement could prevent deaths due to insufficiently tested device modifications.

"The need for rapid approval of design improvements to marketed devices must be weighed against the possibility of introducing unknown risks to patient health from such modifications," the authors wrote in their commentary.

In addition, Redberg said, "A requirement that post-marketing clinical data, including adverse events, be collected and deposited into a public data base would allow for the best identification of patients who could benefit from a device, without slowing market entry."

The growing medical device industry is expected to generate $228 billion in sales by 2015 for technologies ranging from orthopedic knee replacements to cochlear implants, to infusion pumps. Many devices are invasively installed within the body, and the potential complications when they fail can be great.

Examples of avoidable outcomes, according to Redberg and Zheng, include hundreds of failures and five deaths arising from use of the modified Sprint Fidelis defibrillator electrical lead wire made by Medtronic, Inc., prompting a recall, and a similar recall of defibrillator leads marketed by St. Jude Medical, Inc., after 227,000 had been implanted in patients.

The FDA evaluates safety and effectiveness of new, high-risk medical devices before they are marketed, through a process known as premarket approval (PMA). This procedure involves the submission and review of clinical-trials data. However, modifications of existing devices may be approved without additional clinical data, through a less rigorous procedure called a PMA supplement.

"Companies often submit changes to a device one supplement at a time instead of submitting multiple changes in a single application," Redberg and Zheng stated in the commentary. "As a result, each submitted modification is evaluated separately, a process that makes it difficult, if not impossible, to take into account the cumulative effects and interactions of multiple modifications."

The Medtronic and St. Jude Medical devices were modified multiple times through PMA supplements without additional clinical data submission, the authors noted.

Clinicians may favor use of a device based on original research on a much earlier version, with no knowledge of substantial, untested modifications that have been made to the currently available device, they said.

The authors advocated for clear labeling of devices to highlight modifications to physicians and alert them to unevaluated risks.

Story Source:

The above story is based on materials provided by University of California - San Francisco. The original article was written by Jeffrey Norris. Note: Materials may be edited for content and length.


View the original article here

Friday, April 11, 2014

Robotic arm probes chemistry of 3-D objects by mass spectrometry

When life on Earth was first getting started, simple molecules bonded together into the precursors of modern genetic material. A catalyst would have been needed, but enzymes had not yet evolved. One theory is that the catalytic minerals on a meteorite's surface could have jump-started life's first chemical reactions. But scientists need a way to directly analyze these rough, irregularly shaped surfaces. A new robotic system at Georgia Tech's Center for Chemical Evolution could soon let scientists better simulate and analyze the chemical reactions of early Earth on the surface of real rocks to further test this theory.

In a proof-of-concept study, scientists selected a region for analysis on round or irregularly-shaped objects using a 3-D camera on a robotic arm, which mapped the 3-dimentional coordinates of the sample's surface. The scientists programmed the robotic arm to poke the sample with an acupuncture needle. The needle collected a small amount of material that the robot deposited in a nearby mass spectrometer, which is a powerful tool for determining a substance's chemical composition.

"You see the object on a monitor and then you can point and click and take a sample from a particular spot and the robot will go there," said Facundo Fernandez, a professor in the School of Chemistry and Biochemistry, whose lab led the study. "We're using an acupuncture needle that will touch very carefully on the surface of the object and then the robot will turn around and put the material inside of a high resolution mass spectrometer."

The research was published online February 28 in the journal Analyst, a publication of the Royal Society of Chemistry. The work was supported by a National Science Foundation (NSF) Major Research Instrumentation Program (MRI) grant and by the National Science Foundation (NSF) and NASA Astrobiology Program, under the NSF Center for Chemical Evolution.

Mass spectrometry is a powerful tool for analyzing surface chemistry or for identifying biological samples. It's widely used in research labs across many disciplines, but samples for analysis typically have to be cleaned, carefully prepared, and in the case of rocks, cut into thin, flat samples. The new robotic system is the first report of a 3-D mass spectrometry native surface imaging experiment.

"Other people have used an acupuncture needle to poke a sample and then put that in mass spec, but nobody has tried to do a systematic, three-dimensional surface experiment," Fernandez said. "We are trying to push the limits."

To show that the system was capable of probing a three-dimensional object, the researchers imprinted ink patterns on the surfaces of polystyrene spheres. The team then used the robotic arm to model the surfaces, probe specific regions, and see if samples collected were sufficient for mass spectrometry analysis. The researchers were able to detect inks of different colors and create a 3-D image of the object with sufficient sensitivity for their proof-of-principle setup, Fernandez said.

The research was the result of collaboration between Fernandez's group, which specializes in mass spectrometry, and Henrik Christensen's robotics group in the College of Computing. Christensen is the KUKA Chair of Robotics and a Distinguished Professor of Computing. He is also the executive director of the Institute for Robotics and Intelligent Machines (IRIM) at Georgia Tech.

"The initial findings of this study mark a significant step toward using robots for three-dimensional surface experiments on geological material," Christensen said. "We are using the repeatability and accuracy of robots to achieve new capabilities that have numerous applications in biomedical areas such as dermatology."

"It doesn't happen very often that a group in mass spectrometry will have a very talented robotics group next to them," Fernandez said. "If we tried to learn the robotics on our own it could take us a decade, but for them it's something that's not that difficult."

Christensen's team loaned a Kuka KR5 sixx R650 robot to Fernandez's lab for the study. Afterwards, Fernandez's lab purchased their own robot from Universal Robots. They have also upgraded to a new mass spectrometer capable of resolution nearly eight times higher than the one used in the study. They will soon begin replicating early Earth chemistry on rocks and analyzing the reaction products with their robotic sampling system.

"We really want to look at rocks," Fernandez said. "We want to do reactions on rocks and granites and meteorites and then see what can be produced on the surface."

The technology could also be applied to other research fields, Fernandez said. For example, the robot-mass spec combo might be useful to dermatologists who often probe lesions on the skin, which have distinct molecular signatures depending on if the lesion is a tumor or normal skin tissue.

Story Source:

The above story is based on materials provided by Georgia Institute of Technology. Note: Materials may be edited for content and length.


View the original article here

Wednesday, April 9, 2014

Cancer treatment revolution potential with new drug

A revolution in cancer treatment could soon be underway following a breakthrough that may lead to a dramatic improvement in cancer survival rates.

A new study at the University of Warwick, published today in the journal Angewandte Chemie International Edition, has developed a new drug that can manipulate the body's natural signalling and energy systems, allowing the body to attack and shut down cancerous cells.

Called ZL105, the drug is a compound based on the precious metal iridium. The study has found ZL105 could potentially replace currently used anticancer drugs, which become less effective over time, cause a wide-range of side-effects and damage healthy cells as well as cancerous.

Commenting on the breakthrough, University of Warwick researcher and study co-author Dr Isolda Romero-Canelon said "The energy-producing machinery in cancer cells works to the limit as it attempts to keep up with quick proliferation and invasion. This makes cancer cells susceptible to minor changes in the cell 'power-house'. Our drug pushes cancer cells over the limit causing them to slow and shut down, whilst normal cells can cope with its effects."

Preliminary data indicate that the novel drug may be ten times more effective in treating ovarian, colon, melanoma, renal, and some breast cancers, according to data obtained by the US National Cancer Institute. The researchers now aim to expand the study to cancers that are inherently resistant to existing drugs and to those which have developed resistance after a first round of chemotherapy treatments.

Study co-author Professor Peter J. Sadler said "Existing cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked. The drug we have developed is a catalyst and is active at low doses. It can attack cancer cells in multiple ways at the same time, so the cancer is less able to adapt to the treatment. This means the new drugs could be much more effective than existing treatments."

"Platinum-based drugs are used in nearly 50% of all chemotherapeutic regimens, exert their activity by damaging DNA and cannot select between cancerous and non-cancerous cells, leading to a wide-range of side-effects from renal failure to neurotoxicity, ototoxicity, nausea and vomiting.

"In contrast, the new iridium-based drug is specifically designed not to attack DNA, but to have a novel mechanism of action, meaning that it could not only dramatically slow down and halt cancer growth, but also significantly reduce the side effects suffered by patients" argues Professor Sadler.

This research could also lead to substantial improvements in cancer survival rates. "Current statistics indicate that one in every three people will develop some kind of cancer during their life time, moreover approximately one woman dies of ovarian cancer every two hours in the UK according to Cancer Research UK .It is clear that a new generation of drugs is necessary to save more lives and our research points to a highly effective way of defeating cancerous cells" said Dr Romero-Canelon.

Story Source:

The above story is based on materials provided by University of Warwick. Note: Materials may be edited for content and length.


View the original article here

Tuesday, April 8, 2014

'Glue' holding together skin cells, other epithelial tissue more active than realized

The strong mechanical attachments -- the "glue" -- that hold together the cells of the skin and the other epithelial tissues of the body are the adherens junctions.

These junctions are responsible for maintaining the shape and integrity of the sheets of epithelial cells that line such body cavities as the digestive tract, as well as the surfaces of structures such as the heart. Defects in the proteins of these attachments have been implicated as potential contributors to the development and spread of cancer.

Recent research on Drosophila flies, combined with previous studies in cell cultures, are challenging the traditional view that adherens junctions maintain tissue integrity by passively resisting disruptive forces.

In studies with Drosophila embryos, the Princeton University lab of Nobel laureate Eric Wieschaus, Ph.D., has uncovered the first evidence in living organisms that adherens junctions actively respond to mechanical cues by remodeling their own position and intensity, which in turn restructures the cells.

Mo Weng, Ph.D., postdoctoral fellow in the lab, used live imaging and quantitative image analysis of fixed and live embryos to determine that these changes depend on mechanical force mediated by the motor protein myosin and precede the changes in the distribution of cell polarity proteins, such as Bazooka, that are responsible for spatial organization of the cells.

Understanding the regulation and functioning of adherens junctions sheds light on the organization of multi-cellularity -- from cell-cell contacts to the remodeling of tissues and organs during life.

Story Source:

The above story is based on materials provided by Genetics Society of America. Note: Materials may be edited for content and length.


View the original article here

Monday, April 7, 2014

Fewer children at risk for deficient vitamin D

Under new guidelines from the Institute of Medicine, the estimated number of children who are at risk of having insufficient or deficient levels of vitamin D is drastically reduced from previous estimates, according to a Loyola University Chicago Stritch School of Medicine study.

The study, led by Holly Kramer, MD, MPH, and Ramon Durazo-Arvizu, PhD, is published online ahead of print in the Journal of Pediatric Endocrinology and Metabolism.

New Institute of Medicine guidelines say most people get sufficient vitamin D when their blood levels are at or above 20 nanograms per milliliter (ng/mL). The Pediatric Endocrine Society has a similar guideline. However, other guidelines recommend vitamin D levels above 30 ng/mL.

Loyola researchers studied vitamin D data from a nationally representative sample of 2,877 U.S. children and adolescents ages 6 to 18 who participated in the National Health and Nutrition Examination Survey.

The study found that under the Institute of Medicine guidelines, 10.3 percent of children ages 6 to 18 are at risk of inadequate or deficient vitamin D levels. (This translates to an estimated 5.5 million children.)

By comparison, a 2009 study in the journal Pediatrics, which defined sufficient vitamin D levels as greater than 30 ng/mL, found that an estimated 70 percent of people ages 1 to 21 had deficient or insufficient vitamin D levels.

Under previous guidelines, millions of children who had vitamin D levels between 20 and 30 ng/mL would have needed supplementation. Under the Institute of Medicine guidelines, children in this range no longer need to take vitamin D supplements.

The new study found that children at risk of vitamin D deficiency under the Institute of Medicine guidelines are more likely to be overweight, female, non-white and between the ages of 14 and 18.

The Institute of Medicine's new vitamin D guidelines are based on nearly 1,000 published studies and testimony from scientists and other experts. The IOM found that vitamin D is essential to avoid poor bone health, such as rickets. But there have been conflicting and mixed results in studies on whether vitamin D can also protect against cancer, heart disease, autoimmune diseases and diabetes. Moreover, excessive vitamin D can damage the kidneys and heart, the IOM found.

Story Source:

The above story is based on materials provided by Loyola University Health System. Note: Materials may be edited for content and length.


View the original article here

Sunday, April 6, 2014

Twenty-five percent of breast cancer survivors report financial decline due to treatment

Four years after being treated for breast cancer, a quarter of survivors say they are worse off financially, at least partly because of their treatment, according to a new study led by University of Michigan Comprehensive Cancer Center researchers. In addition, 12 percent reported that they still have medical debt from their treatment.

Financial decline varied significantly by race, with Spanish-speaking Latinas most likely to be impacted. Debt was reported more frequently in English-speaking Latinas and Blacks, the study found. Results appear in the Journal of Clinical Oncology.

"As oncologists, we are proud of the advances in our ability to cure an increasing proportion of patients diagnosed with breast cancer. But as treatments improve, we must ensure that we do not leave these patients in financial ruin because of our efforts," says study author Reshma Jagsi, M.D., D.Phil., associate professor of radiation oncology at the University of Michigan Medical School.

The researchers surveyed women in Detroit and Los Angeles who had been diagnosed with early stage breast cancer, based on data obtained from the National Cancer Institute's Surveillance, Epidemiology and End Results population-based registry. Women were surveyed about nine months after diagnosis and again about four years later, with 1,502 women responding to both surveys.

The surveys asked about patients' perceptions of whether they were worse off financially since their diagnosis, and whether that has caused long-term challenges. For example, patients were asked if they had altered their medical care because of financial concerns, by skipping medication or by missing a doctor's appointment or a mammogram. Other questions looked at broader hardships, such as going without health insurance, having utilities turned off or moving out of their home.

Blacks and English-speaking Latinas were more likely than Whites to have experienced one of these issues. Other factors that made a woman more likely to experience these hardships include age under 65, household income under $50,000, part-time work at diagnosis, reduced work hours after diagnosis, lack of substantial prescription drug coverage, breast cancer recurrence, and undergoing chemotherapy.

"These patients are particularly vulnerable to financial distress," Jagsi says. "We need to ensure appropriate communication between patients and their doctors regarding the financial implications of a cancer diagnosis and treatment decisions to help reduce this long-term burden."

Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


View the original article here

Friday, April 4, 2014

State-of-the-state on genetic-based testing, treatment for breast cancer revealed

Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer. The paper entitled "Personalized Therapy for Breast Cancer" was accepted on March 17, 2014, for publication in Clinical Genetics. The paper discusses targeted therapies, new biomarkers, and the quality of commercially available testing methods.

Genomic testing is changing the way breast cancer is diagnosed and treated. By examining a woman's genes to look for specific mutations or biomarkers, treatment can be personalized to the tumor cell's biology and a woman's genetics.

"A personalized approach increases the precision and success of breast cancer treatment," said Gregory Tsongalis, PhD, director of Molecular Pathology at Norris Cotton Cancer Center and lead author of the paper. "Molecular profiling exposes a tumor's Achilles' heel. We can see what messages the tumor cells are receiving and sending. It is a biological intelligence gathering mission in an attempt to interrupt the disease.

According to Tsongalis large scale genetic testing of breast cancer is not yet part of routine clinical care as it is with lung and colon cancers, even though he and his team run a genetics laboratory for routine cancer care. Genetic testing according to Tsongalis is a powerful weapon in the diagnosis and treatment of breast cancer.

With results from the genetic testing of a tumor cell's biology, clinicians categorize breast cancer in ways that allow them to select the most effective treatments. Based on genetic biomarkers, there are three categories of breast cancer:

  1. ER-positive breast cancer needs hormones, such as estrogen to grow. Estrogen fuels cancer cell growth, stops cancer cells from dying, and helps the cells lay down roots to maintain blood supply for tumors. ER-positive cancers are less aggressive and often treated with drugs that are selective estrogen receptor modulators (SERM), such as Tamoxifen, Raloxifene, Toremifene and aromatese inhibitors (AIs) such as Letrozole, Anastrozole and Exemestane. SERM drugs block estrogen from telling cancer cells to divide and grow; they have been shown successful in treating as well as preventing ER positive breast cancer. AIs block intake of estrogen in the system and reduce estrogen levels in serum, tissue, and tumor cells. AIs are commonly used in post-menopausal women.
  2. HER2 -positive breast cancer cells contain large amounts of protein that help them grow and multiply. Medications turn off the production of protein to stop tumor growth and kill cancer cells. HER2 treatments include Trastuzumab, Laptinib, Pertuzumab, and Trastuzumab Emtansine.
  3. Triple negative (ER-negative/PR-negative/HER2-negative) breast cancer is the most aggressive type and has the poorest clinical outcome. There is no approved personalized therapy for triple negative, but research has identified six subtypes of tumors. This is the first step in identifying biomarkers that can lead to the development of personalized treatments.

"Genomic testing of breast cancer has expanded our understanding of the disease process and has proven more effective than traditional laboratory tests," said Tsongalis. "At NCCC all of our breast cancer patients are tested for abnormal copies of the HER2 gene using specially designed DNA probes. New biomarkers and the reclassification of cancers based on these biomarkers has led to the development of new, effective treatments that can be personalized to an individual breast cancer patient."

Story Source:

The above story is based on materials provided by The Geisel School of Medicine at Dartmouth. Note: Materials may be edited for content and length.


View the original article here

Thursday, April 3, 2014

Plasma tool for destroying cancer cells

Plasma medicine is a new and rapidly developing area of medical technology. Specifically, understanding the interaction of so-called atmospheric pressure plasma jets with biological tissues could help to use them in medical practice.

Under the supervision of Sylwia Ptasinska from the University of Notre Dame, in Indiana, USA, Xu Han and colleagues conducted a quantitative and qualitative study of the different types of DNA damage induced by atmospheric pressure plasma exposure, the paper is published inThe European Physical Journal D, as part of a special issue on nanoscale insights into Ion Beam Cancer Therapy. This approach, they hope, could ultimately lead to devising alternative tools for cancer therapy as well as applications in hospital hygiene, dental care, skin diseases, antifungal care, chronic wounds and cosmetics treatments.

To investigate the DNA damage from the so-called non-thermal Atmospheric Pressure Plasma Jet (APPJ), the team adopted a common technique used in biochemistry, called agarose gel electrophoresis. They studied the nature and level of DNA damage by plasma species, so-called reactive radicals, under two different conditions of the helium plasma source with different parameters of electric pulses.

They also identified the effect of water on DNA damage. To do so, they examined the role of reactive radicals involved in DNA damage processes occurring in an aqueous environment. They then compared them to previous results obtained in dry DNA samples.

The next step would involve investigating plasma made from helium mixtures with different molecular ratios of other gases, such as oxygen, nitrous oxide, carbon dioxide and steam, under different plasma source conditions. The addition of another gas is expected to increase the level of radical species, such as reactive oxygen species and reactive nitrogen species, known to produce severe DNA damage. These could, ultimately, help to destroy cancerous tumour cells.

Story Source:

The above story is based on materials provided by Springer Science+Business Media. Note: Materials may be edited for content and length.


View the original article here

Tuesday, April 1, 2014

WHO opens public consultation on draft sugars guideline

WHO is launching a public consultation on its draft guideline on sugars intake. When finalized, the guideline will provide countries with recommendations on limiting the consumption of sugars to reduce public health problems like obesity and dental caries (commonly referred to as tooth decay).

Comments on the draft guideline will be accepted via the WHO web site from 5 through 31 March 2014. Anyone who wishes to comment must submit a declaration of interests. An expert peer-review process will happen over the same period. Once the peer-review and public consultation are completed, all comments will be reviewed, the draft guidelines will be revised if necessary and cleared by WHO’s Guidelines Review Committee before being finalized.

New draft guideline proposals

WHO’s current recommendation, from 2002, is that sugars should make up less than 10% of total energy intake per day. The new draft guideline also proposes that sugars should be less than 10% of total energy intake per day. It further suggests that a reduction to below 5% of total energy intake per day would have additional benefits. Five per cent of total energy intake is equivalent to around 25 grams (around 6 teaspoons) of sugar per day for an adult of normal Body Mass Index (BMI).

The suggested limits on intake of sugars in the draft guideline apply to all monosaccharides (such as glucose, fructose) and disaccharides (such as sucrose or table sugar) that are added to food by the manufacturer, the cook or the consumer, as well as sugars that are naturally present in honey, syrups, fruit juices and fruit concentrates.

Much of the sugars consumed today are “hidden” in processed foods that are not usually seen as sweets. For example, 1 tablespoon of ketchup contains around 4 grams (around 1 teaspoon) of sugars. A single can of sugar-sweetened soda contains up to 40 grams (around 10 teaspoons) of sugar.

The draft guideline was formulated based on analyses of all published scientific studies on the consumption of sugars and how that relates to excess weight gain and tooth decay in adults and children.

Note to editors

Papers published with findings of two systematic reviews (analyses of published scientific studies) commissioned by WHO that informed the development of the draft guidelines:

For more information please contact:

Tarik Jasarevic
WHO, Geneva
Communications Officer
Telephone: +41 22 791 5099
Mobile: +41 79367 6214
E-mail:jasarevict@who.int

Glenn Thomas
WHO, Geneva
WHO Communications Officer
Telephone: +41 22 791 3983
Mobile: +41 79 509 0677
E-mail:thomasg@who.int


View the original article here